Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk

Prostate

Volumn 71, Issue 13, 2011, Pages 1382-1389

  Amirian, E Susan ^a   Ittmann, Michael M ^a,b   Scheurer, Michael E ^a,b  

^a Dan L Duncan Cancer Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

arachidonic acid; prostate cancer; single nucleotide polymorphisms

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONIC ACID; CYCLOOXYGENASE 2; LEUKOTRIENE A4 HYDROLASE; PROSTAGLANDIN E SYNTHASE; PROSTAGLANDIN E SYNTHASE 2; UNCLASSIFIED DRUG;

AGED; ARACHIDONIC ACID METABOLISM; ARTICLE; BODY MASS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM;

5-LIPOXYGENASE-ACTIVATING PROTEINS; AGED; ARACHIDONIC ACID; CYCLOOXYGENASE 2; EPOXIDE HYDROLASES; GENOTYPE; HAPLOTYPES; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK;

EID: 80051667117     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21354     Document Type: Article

References (43)

1. Patel MI, Kurek C, Dong Q,. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008; 179 (5): 1668-1675.
2. Ghosh J, Myers CE, Jr., Arachidonic acid metabolism and cancer of the prostate. Nutrition 1998; 14 (1): 48-49.
3. Harizi H, Corcuff JB, Gualde N,. Arachidonic-acid-derived eicosanoids: Roles in biology and immunopathology. Trends Mol Med 2008; 14 (10): 461-469.
4. Taber L, Chiu CH, Whelan J,. Assessment of the arachidonic acid content in foods commonly consumed in the American diet. Lipids 1998; 33 (12): 1151-1157. (Pubitemid 29061879)
5. Rose DP, Connolly JM,. Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr Cancer 2000; 37 (2): 119-127.
6. Rose DP, Connolly JM,. Effects of fatty acids and eicosanoid synthesis inhibitors on the growth of two human prostate cancer cell lines. Prostate 1991; 18 (3): 243-254.
7. Liu B, Maher RJ, De Jonckheere JP, Popat RU, Stojakovic S, Hannun YA, Porter AT, Honn KV,. 12(S)-HETE increases the motility of prostate tumor cells through selective activation of PKC alpha. Adv Exp Med Biol 1997; 400B: 707-718.
8. Peters-Golden M, Henderson WR, Jr., Leukotrienes. N Engl J Med 2007; 357 (18): 1841-1854.
9. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC,. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68 (19): 7750-7759.
10. Wang J, John EM, Ingles SA,. 5-lipoxygenase and 5-lipoxygenase-activating protein gene polymorphisms, dietary linoleic acid, and risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17 (10): 2748-2754.
11. Hussain T, Gupta S, Mukhtar H,. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 2003; 191 (2): 125-135. (Pubitemid 36255597)
12. Hyde CA, Missailidis S,. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. Int Immunopharmacol 2009; 9 (6): 701-715.
13. Panguluri RC, Long LO, Chen W, Wang S, Coulibaly A, Ukoli F, Jackson A, Weinrich S, Ahaghotu C, Isaacs W, Kittles RA,. COX-2 gene promoter haplotypes and prostate cancer risk. Carcinogenesis 2004; 25 (6): 961-966. (Pubitemid 38886082)
14. Fernandez P, de Beer PM, van der Merwe L, Heyns CF,. COX-2 promoter polymorphisms and the association with prostate cancer risk in South African men. Carcinogenesis 2008; 29 (12): 2347-2350.
15. Shahedi K, Lindstrom S, Zheng SL, Wiklund F, Adolfsson J, Sun J, Augustsson-Balter K, Chang BL, Adami HO, Liu W, Gronberg H, Xu J,. Genetic variation in the COX-2 gene and the association with prostate cancer risk. Int J Cancer 2006; 119 (3): 668-672. (Pubitemid 43955722)
16. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS,. COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 2007; 97 (4): 557-561. (Pubitemid 47258446)
17. Zhu W, Wei BB, Shan X, Liu P,. -765G>C and 8473T>C polymorphisms of COX-2 and cancer risk: A meta-analysis based on 33 case-control studies. Mol Biol Rep 2010; 37 (1): 277-288.
18. Danforth KN, Hayes RB, Rodriguez C, Yu K, Sakoda LC, Huang WY, Chen BE, Chen J, Andriole GL, Calle EE, Jacobs EJ, Chu LW, Figueroa JD, Yeager M, Platz EA, Michaud DS, Chanock SJ, Thun MJ, Hsing AW,. Polymorphic variants in PTGS2 and prostate cancer risk: Results from two large nested case-control studies. Carcinogenesis 2008; 29 (3): 568-572. (Pubitemid 351404873)
19. Hsing AW, Sakoda LC, Chua S, Jr., Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86 (3): s843-s857.
20. Mistry T, Digby JE, Desai KM, Randeva HS,. Obesity and prostate cancer: A role for adipokines. Eur Urol 2007; 52 (1): 46-53. (Pubitemid 46803036)
21. Clarke NW, Brown MD,. The influence of lipid metabolism on prostate cancer development and progression: Is it time for a closer look ? Eur Urol 2007; 52 (1): 3-4. (Pubitemid 46803041)
22. Wang MH, Helzlsouer KJ, Smith MW, Hoffman-Bolton JA, Clipp SL, Grinberg V, De Marzo AM, Isaacs WB, Drake CG, Shugart YY, Platz EA,. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II. Prostate 2009; 69 (8): 874-885.
23. Freedland SJ, Platz EA,. Obesity and prostate cancer: Making sense out of apparently conflicting data. Epidemiol Rev 2007; 29: 88-97. (Pubitemid 47229642)
24. Wang W, Bergh A, Damber JE,. Cyclooxygenase-2 expression correlates with local chronic inflammation and tumor neovascularization in human prostate cancer. Clin Cancer Res 2005; 11 (9): 3250-3256. (Pubitemid 40627872)
25. Chaudry A, McClinton S, Moffat LE, Wahle KW,. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991; 64 (6): 1157-1160.
26. Chaudry AA, Wahle KW, McClinton S, Moffat LE,. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: Effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994; 57 (2): 176-180. (Pubitemid 24144205)
27. Ihara A, Wada K, Yoneda M, Fujisawa N, Takahashi H, Nakajima A,. Blockade of leukotriene B4 signaling pathway induces apoptosis and suppresses cell proliferation in colon cancer. J Pharmacol Sci 2007; 103 (1): 24-32. (Pubitemid 46175592)
28. Bray MA,. Leukotriene B4: An inflammatory mediator with vascular actions in vivo. Agents Actions Suppl 1982; 11: 51-61.
29. Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R, Conklyn MJ, Smith MA, Hackman BC, Wimberly DJ, Milici AJ, Scampoli DN, Cheng JB, Pillar JS, Pazoles CJ, Doherty NS, Melvin LS, Reiter LA, Biggars MS, Falkner FC, Mitchell DY, Liston TE, Showell HJ,. Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995; 92 (2): 517-521.
30. Holloway JW, Barton SJ, Holgate ST, Rose-Zerilli MJ, Sayers I,. The role of LTA4H and ALOX5AP polymorphism in asthma and allergy susceptibility. Allergy 2008; 63 (8): 1046-1053.
31. Rioux N, Castonguay A,. Inhibitors of lipoxygenase: A new class of cancer chemopreventive agents. Carcinogenesis 1998; 19 (8): 1393-1400. (Pubitemid 28409837)
32. Helgadottir A, Manolescu A, Helgason A, Thorleifsson G, Thorsteinsdottir U, Gudbjartsson DF, Gretarsdottir S, Magnusson KP, Gudmundsson G, Hicks A, Jonsson T, Grant SF, Sainz J, O'Brien SJ, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Levey AI, Abramson JL, Reilly MP, Vaccarino V, Wolfe ML, Gudnason V, Quyyumi AA, Topol EJ, Rader DJ, Thorgeirsson G, Gulcher JR, Hakonarson H, Kong A, Stefansson K,. A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat Genet 2006; 38 (1): 68-74. (Pubitemid 43011884)
33. Tobin DM, Vary JC, Jr, Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S, King MC, Hawn TR, Moens CB, Ramakrishnan L,. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010; 140 (5): 717-730.
34. Ahima RS, Osei SY,. Adipokines in obesity. Front Horm Res 2008; 36: 182-197.
35. Altekruse SF, Huang L, Cucinelli JE, McNeel TS, Wells KM, Oliver MN,. Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States. 1999-2001. Cancer Epidemiol Biomarkers Prev 2010; 19 (6): 1460-1467.
36. Nitz I, Fisher E, Grallert H, Li Y, Gieger C, Rubin D, Boeing H, Spranger J, Lindner I, Schreiber S, Rathmann W, Gohlke H, Doring A, Wichmann HE, Schrezenmeir J, Doring F, Illig T,. Association of prostaglandin E synthase 2 (PTGES2) Arg298His polymorphism with type 2 diabetes in two German study populations. J Clin Endocrinol Metab 2007; 92 (8): 3183-3188. (Pubitemid 47236389)
37. Fischer A, Grallert H, Bohme M, Gieger C, Boomgaarden I, Heid I, Wichmann HE, Doring F, Illig T,. Association analysis between the prostaglandin E synthase 2 R298H polymorphism and body mass index in 8079 participants of the KORA study cohort. Genet Test Mol Biomarkers 2009; 13 (2): 223-226.
38. Wung SF, Aouizerat BE,. Candidate genes of the 5-lipoxygenase pathway in acute coronary syndrome: A pilot study. Biol Res Nurs 2008; 9 (4): 280-292.
39. Assimes TL, Knowles JW, Priest JR, Basu A, Volcik KA, Southwick A, Tabor HK, Hartiala J, Allayee H, Grove ML, Tabibiazar R, Sidney S, Fortmann SP, Go A, Hlatky M, Iribarren C, Boerwinkle E, Myers R, Risch N, Quertermous T,. Common polymorphisms of ALOX5 and ALOX5AP and risk of coronary artery disease. Hum Genet 2008; 123 (4): 399-408.
40. Crosslin DR, Shah SH, Nelson SC, Haynes CS, Connelly JJ, Gadson S, Goldschmidt-Clermont PJ, Vance JM, Rose J, Granger CB, Seo D, Gregory SG, Kraus WE, Hauser ER,. Genetic effects in the leukotriene biosynthesis pathway and association with atherosclerosis. Hum Genet 2009; 125 (2): 217-229.
41. Herb F, Thye T, Niemann S, Browne EN, Chinbuah MA, Gyapong J, Osei I, Owusu-Dabo E, Werz O, Rusch-Gerdes S, Horstmann RD, Meyer CG,. ALOX5 variants associated with susceptibility to human pulmonary tuberculosis. Hum Mol Genet 2008; 17 (7): 1052-1060. (Pubitemid 351426039)
42. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K,. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36 (3): 233-239. (Pubitemid 38282747)
43. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, Wang J, Sylvester J, Holbrook J, Wise R, Weiss ST, Barnes K,. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173 (4): 379-385. (Pubitemid 43228324)